Aquestive Therapeutics Faces FDA Hurdles for Anaphylm, Extends Cash Runway — Aquestive Therapeutics, Inc.

Event summary

Aquestive Therapeutics received a Complete Response Letter (CRL) from the FDA for Anaphylm, citing human factors validation and packaging issues.
The company plans to resubmit Anaphylm's NDA in Q3 2026, following a Type A meeting with the FDA within 30 days.
Aquestive extended its revenue-sharing agreement with RTW Investments to June 30, 2027, and secured a $5 million share purchase commitment.
Full-year 2025 revenue was $44.5 million, down 3% from 2024, with a non-GAAP adjusted EBITDA loss of $49.7 million.
The company expects to end FY2026 with $70 million in cash and cash equivalents.

The big picture

Aquestive Therapeutics is navigating a critical regulatory hurdle with Anaphylm, its lead product candidate for severe allergic reactions. The FDA's CRL highlights the challenges of bringing innovative drug delivery systems to market, particularly those that deviate from established standards like auto-injectors. The company's ability to secure additional funding and maintain its cash runway will be crucial as it works to address the FDA's concerns and prepare for potential commercialization. The broader biotech sector continues to face regulatory scrutiny, with investors closely watching how companies like Aquestive manage these challenges while advancing their pipelines.

What we're watching

Regulatory Pathway: Whether Aquestive can successfully address the FDA's concerns and secure Anaphylm's approval by Q3 2026.
Financial Stability: The pace at which Aquestive burns through its $70 million cash reserve and its ability to secure additional funding.
Market Opportunity: How the potential approval of Anaphylm and AQST-108 could position Aquestive in the allergy and dermatology markets.